Given the poor ability of intramuscular mRNA COVID-19 vaccines to induce robust immunity in the respiratory mucosa, a push for a nasal vaccine strategy is needed.
No takes yet. Share an insight, caveat, or question.
Topol et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: